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Abstract—Today COXIBs are used in the treatment of arthritis 
and many other painful conditions in selected patients with high 
gastrointestinal risk and low cardiovascular (CV) risk. Previously, we 
have identified an unexpected mechanism of action of a traditional 
non-steroidal anti-inflammatory drug (NSAID) (diclofenac) and a 
specific inhibitor of cyclooxygenase-2 (COXIB) (lumiracoxib) 
demonstrating that they possess weak competitive antagonism at the 
thromboxane receptor (TP). We hypothesize that modifying the 
structure of a known COXIB so that it becomes also a more potent 
TP antagonist will preserve the anti-inflammatory and 
gastrointestinal safety typical of COXIBs and prevent the CV risk 
associated with long term therapy. 
 
Keywords—Cyclooxygenase, inflammation, lumiracoxib, 
thromboxane A2.  
I. INTRODUCTION 
ONSTEROIDAL anti-inflammatory drugs (NSAIDs) are 
a group of medications that provide anti-
inflammatory/analgesic and anti-pyretic activities. Their main 
mechanism of action is based on the inhibition of the 
cyclooxygenases (COXs), which are responsible of the 
transformation of arachidonic acid in a series of prostanoids 
[1] (Fig. 1). COX-1 is the constitutive isoform expressed in 
most tissues and is involved in gastric cytoprotection and 
haemostatic integrity [2]. COX-2, on the other hand, is the 
inducible isoform mainly expressed in response to 
inflammatory stimuli and is involved in inflammation, 
tumorigenesis and inhibition of platelet aggregation and 
vasodilatation [2]. In the 1990s after the identification of the 
second COX isoform a new class of NSAIDs or COX-2 
selective inhibitors (COXIBs) was developed [3] to improve 
the gastrointestinal safety of the traditional NSAIDs. The 
therapeutic use of COXIBs is however limited by potential 
cardiovascular (CV) hazard associated with their long term 
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therapy [4]. These effects have been hypothesized by the 
imbalance theory, which assumes that any COXIB that 
reduces endothelial-derived prostacyclin (PGI2, a platelet 
aggregation inhibitor and vasodilator) without affecting 
platelet-derived thromboxane A2 (TXA2, a platelet aggregation 
stimulator and vasoconstrictor) will predispose to a 
prothrombotic state [5]. Therefore, the increasing CV hazard 
led to the withdrawn from the market of rofecoxib or Vioxx by 
Merck and Valdecoxib (Bextra) by Pfizer [6] with significant 
economic and image loss for the companies [7]. Yet, there is 
great interest in designing new COXIBs with reduced CV 
adverse effects to extend their use to patients that are at high 
CV risk. 
 
 
Fig. 1 The arachidonic acid cascade: COX-1 is the constitutive 
isoform, whereas the COX-2 is the inducible isoform responsible for 
the transformation of arachidonic acid in prostanoids [15] 
 
Recently we observed an unexpected mechanism of action 
of diclofenac, a potent and widely used anti-inflammatory 
drug, with a non selective COX profile, as well as of its 
derivative, lumiracoxib, a selective COX-2 inhibitor. Both 
compounds displayed a weak competitive antagonism at the 
TXA2 receptor (TP) [8], however not sufficiently potent for 
therapeutic use.  
TP receptor is a G-protein coupled receptor, which exists in 
2 isoforms named TPα and TPβ. It is mainly coupled to Gq 
protein [9] but also to G12/13 and Gs, [10]. Activation of TP 
receptors induces platelet shape change and aggregation, 
constriction of vascular smooth-muscle cells, providing a 
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stimulus for causing thrombus formation, contraction of 
pulmonary venous and arterial smooth muscle [11]-[14]. 
We hypothesize that modifying the structure of a known 
COXIB so that it becomes also a potent TP receptor antagonist 
will preserve the anti-inflammatory and gastrointestinal safety 
profile typical of COXIBs, while preventing the reported 
increase in CV risk associated with long term therapy resulting 
from the imbalance between the decrease in endothelial PGI2 
and the platelet TXA2 production [15].  
These findings lead us to a new study, the modulation of the 
structure of lumiracoxib in order obtain new NSAIDs with a 
more balanced COXIB and TP receptor antagonist properties 
leading to a third generation of NSAIDs with an improved CV 
profile [16].  
 
 
Fig. 2 Pharmacological modulators of thromboxane A2 (TXA2) and 
prostacyclin (PGI2). Aspirin (ASA) inhibits COX-1 and COX-2 
suppressing the production of both TXA2 and PGI2. TP antagonist 
prevents activation of the TP receptor by all possible mediators, 
including isoprostanes. COXIBs block COX-2 and inhibit the 
production of inflammatory prostaglandins, but also suppress the 
endogenous formation of PGI2 in endothelial cells without affecting 
TXA2 generation. This might increase the risk of a major 
cardiovascular event. A third-generation NSAID might possess anti-
inflammatory properties, together with an improved gastrointestinal 
(GI) and CV profile [15] 
 
II. METHODS  
The carboxylic function of the lead was replaced by non-
classical isosteres of acid groups giving rise to different 
compounds.  
The anti-aggregatory potencies of the compounds, 
expressed as IC50 values were assessed in washed human 
platelets by Born-turbidimetric assay. Platelets were isolated 
from human blood of healthy volunteers with no history of 
cardiovascular diseases in the presence of the anticoagulant 
CPD (Citrate Phosphate Dextrose solution: sodium citrate, 
dihydrate, 26.3g/L; dextrose, monohydrate, 25.5g/L; citric 
acid, anhydrous 3.27g/L; monobasic sodium phosphate, 
monohydrate, 2.22g/L). Buffy coat was treated with 100µM 
acetylsalicylic acid and buffy coat was centrifuged at 280g for 
15min at room temperature to obtain the platelet-rich plasma 
(PRP). PRP was centrifuged at 650g for 10min at room 
temperature. The pelleted platelets were suspended in washing 
buffer (mM composition: citric acid monohydrate 39, glucose 
monohydrate 5, KCl 5, CaCl2 2, MgCl2 x 6H2O 1, NaCl 103, 
pH 6.5), recentrifuged at 650g for 15min at room temperature, 
and resuspended in 15ml of HBSS (Hank’s Balanced Salt 
Solution: CaCl2·2H2O 0.185g/L; KCl 0.40g/L; KH2PO4 0.06 
g/L; MgCl2·6H2O 0.10g/L; MgSO4·7H2O 0.10g/L; NaCl 8.00 
g/L; NaHCO3 0.35g/L; Na2HPO4 0.048g/L; D-glucosio 1.00 
g/L). After the incubation with drug or vehicle (DMSO, 
maximum 0.2%, v:v) for 5min at 37°C, the platelet 
aggregation was induced by U46619 (0.1-0.5µM) under 
continuous stirring. The aggregation was monitored for 6 
minutes. 
The TP receptor binding were assessed by radioligand 
binding assay in Human Embryonic Kidney cells (HEK 293) 
cells (ATCC, Manassas, VA) transfected with human TPα 
using the transfecting agent Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA). The transfection mix Lipofectamine 
2000/DNA was prepared in Opti-MEM I Medium which was 
optimized at 2:1 ratio and later added to the cells. The cells 
were labeled with the specific antagonist of the receptor [3H]-
SQ29,548 (Perkin-Elmer, Boston, MA) and the radioactivity 
was measured by liquid scintillation counting (Ultima Gold; 
Packard Instruments, Meriden, CT).  
HEK293 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% fetal 
bovine serum (FBS), 2mM glutamine, 50 U ml-1 penicillin, 
100µg ml-1 streptomycin, and 20mM HEPES buffer, pH 7.4, at 
37°C in a humidified atmosphere of 95% air and 5% CO2.  
COXIB activity was studied in isolated human lympho-
monocytes. The expression of COX-2 was induced by 
lipopolysaccharide (LPS) (from E. coli, serotype 0111:B4; 10 
µg ml-1, overnight, 37°C). The activity of COX-2 was assessed 
through the Prostaglandin E2 (PGE2) production, a marker of 
activity of COX-2 detected by immunoenzymatic assay (EIA) 
(PGE2 EIA kit, Cayman Chemical). Different concentrations 
of the tested compounds were used in order to evaluate the 
IC50 values. Prostanoid concentrations in each sample were 
calculated from PGE2 standard curves. IC50 of the compounds 
were calculated versus the maximal PGE2 production. 
COX-1 inhibition was performed in washed human platelets 
suspension (2 x 108 cells ml-1). Platelets were treated (15min) 
with increasing concentration of the tested compounds, and 
incubated at 37°C in a Dubnoff bath. Calcium ionophore 
(A23187, 2µM) was added to test tube samples. After an 
incubation period of 10min at 37°C, the samples were 
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centrifuged at 5000g for 5min at 4°C. In the supernatant 
obtained after centrifugation, the TXB2 production was 
evaluated through the EIA.  
III. RESULTS  
All the synthesized compounds were tested for their COX-2 
inhibitory activity, TP binding affinity as well as antagonist 
property, and the results are reported in Table I. PGE2 
production was used as a marker of COX-2 activity in human 
lympho-monocytes following treatment with 10µg/mL aspirin 
and overnight pretreatment with 10µg/mL LPS to induce 
COX-2 expression. As expected, our data confirmed that 
lumiracoxib is a rather potent COX-2 inhibitor with a reported 
IC50 of 0.0046 µM, while compound 1, 2 and 3 showed similar 
IC50s in the range of 0.025-0.016 μM (Fig. 3 (a)). In addition, 
while compounds 1 was almost inactive at the TP receptor, 
compound 2 was shown to display a slight (less than two-fold) 
more potent antagonistic activity at the TP receptor with 
respect to lumiracoxib, however less potent than compound 4 
(IC50 = 12.8 and 3.37µM, respectively). These data were 
determined by measuring the inhibition of human washed 
platelet aggregation stimulated with 0.5µM of U46619 as TP 
agonist. Compound 4 resulted to posses the highest affinity of 
all the derivatives tested for the TP receptor with a Ki value of 
1.4 µM, more than fifty-fold more potent than lumiracoxib (Ki 
value= 73.5 µM). Ki values were determined in competition 
studies using the specific TP receptor antagonist 
[3H]SQ29,548 as labeled ligand for the human TPα receptor 
expressed in recombinant cells. 
 
TABLE I 
COX-2 INHIBITORY ACTIVITY, THROMBOXANE A2 ANTAGONISM AND TPα 
RECEPTOR AFFINITY FOR DICLOFENAC, LUMIRACOXIB AND SYNTHESIZED 
COMPOUNDS 1-4 
Compound 
COX-2  
IC50 ± %CV 
[µM] 
Aggregation  
IC50 ± %CV 
[µM] 
TPα  
Ki ± %CV 
[µM] 
Diclofenac 0.0015 ± 40 16.00 ± 17 42 ± 45 
Lumiracoxib 0.0046 ± 35 21.3 ± 10 73.5 ± 54 
aCompound 1 0.025 ± 95 10% inhib. (60 µm) Not tested 
aCompound 2 0.016 ± 44 12.8 ± 5 61 ± 45 
aCompound 3 0.025 ± 54 26.7 ± 15 Not tested 
aCompound 4 0.65 ± 91 3.37 ± 16 1.4 ± 20 
a 1: 2-[(2-chloro-6-fluorophenyl)amino]-N-hydroxy-5-methyl-benzene-
acetamide; 2: N-(2-chloro-6-fluorophenyl)-4-methyl-2-(1H-tetrazol-5-
ylmethyl)-benzenamine; 3: 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-
benzoic acid; 4: N-[[2-[(2-chloro-6-fluorophenyl)amino]-5-
methylphenyl]methyl]-1,1,1-trifluoro-methansulfonamide. Synthesis of 
compounds 1-4 is reported in [16]. 
 
COX-2/COX-1 selectivity of diclofenac, lumiracoxib and 
the two most interesting compounds of the series, compound 2 
and 4 were further investigated. COX-1 activity was assessed 
in terms of inhibition of TXB2 production, a stable metabolite 
of TXA2, induced by calcium ionophore. As expected, 
diclofenac resulted, by far, to be the most potent COX-1 
inhibitor, while concentration-response curves of Fig. 3 (b) 
clearly show that all the other derivatives posses a COX-1 
potency similar to lumiracoxib. 
Overall, among of all the compounds under investigation 
only compound 4 displayed rather balanced properties as TP 
antagonist and COXIB inhibitor (IC50 TP/COX-2 = 5.2 versus 
IC50 TP/COX-2 = 4630 for lumiracoxib). In addition, 
compound 4 also displays about 25-fold COX-2 versus COX-
1 selectivity.  
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Fig. 3 (a) Evaluation of COX-2 activity in terms of release of PGE2 in 
isolated human monocytes. Data are expressed as percent inhibition 
of PGE2 release vs. untreated controls. Error bars represent mean ± 
SE of at least three independent experiments performed in duplicate. 
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Fig. 3 (b) Evaluation of COX-1 activity in terms of release of TXB2 
(metabolite of TXA2) from washed platelets during clotting. Data are 
expressed as percent inhibition of TXB2 release vs. untreated 
controls. Error bars represent mean ± SE of at least three independent 
experiments performed in duplicate. 
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IV. CONCLUSION 
Our results show that structure-activity analysis allowed us 
to obtain prototypes of new chemical entities endowed with 
higher TP antagonist potencies and a more balanced COX-2 
selectivity compared to lumiracoxib. The modification of 
existing drugs targeted against COX-2 (lumiracoxib) can lead 
to a new molecule with obvious advantage in the 
pharmacodynamic properties. Further studies will be certainly 
necessary to confirm these results in in vivo animal models. 
These compounds are critical for the innovation of the 
pharmacological treatment of patients that require long-term 
therapy with anti-inflammatory drugs and are at high CV risk. 
In rheumatoid arthritis COXIBs are used in long term therapy, 
typically in a regimen that consists of the administration for 15 
days followed by a washout period of 1-2 months, in order to 
reduce the CV hazard. A third generation NSAID with a safer 
CV profile could have an impact on the duration and 
ameliorate the management of therapy not only in patients 
affected by rheumatoid arthritis or other painful conditions but 
also by selected form of cancer.  
ACKNOWLEDGMENTS 
This work was supported in part by a grant from Regione 
Lombardia (Progetto Ex-ASTIL ID 16755-Rif. SAL-02 to 
G.E.R.) and Fondazione Banca del Monte di Lombardia 
(Funding programme 2010 to G.E.R.). This work was partially 
supported by a MIUR Grant (PRIN 2009) to RF. 
REFERENCES  
[1] A. L. Blobaum, L. J. Marnett, ″Structural and functional basis of 
cyclooxygenase inhibition″, J. Med. Chem. 50, 1425 – 1441, 2007. 
[2] Morita, I. “Distinct functions of COX-1 and COX-2,” Prostaglandins 
Other Lipid Mediat. 68–69, 165–175, 2002. 
[3] DeWitt, D.L, “Cox-2-selective inhibitors: the new super aspirins”. Mol. 
Pharmacol. 55, 625–631, 1999. 
[4] T. Grosser, S. Fries, G.A.FitzGerald, “Biological basis for the 
cardiovascular consequences of COX-2 inhibition: therapeutic 
challenges and Opportunities,” J. Clin. Invest. 116, 4–15, 2006. 
[5]  G. A. FitzGerald, ″COXIBs and cardiovascular disease,” N. Engl. J. 
Med. 351, 1709 – 1711, 2004. 
[6] T. Grosser, S. Fries, G. A. FitzGerald, ″Biological basis for the 
cardiovascular consequences of COX-2 inhibition: therapeutic 
challenges and opportunities,” J. Clin. Invest. 116, 4–15, 2006. 
[7] J. M. Dogn, C. T. Supuran, D. Pratico, “Adverse cardiovascular effects 
of the COXIBs,” J. Med. Chem. 48, 2251 –2257, 2005. 
[8] E. Selg, C. Buccellati, M. Andersson, G.E. Rovati, M. Ezinga, A. Sala, 
A.K. Larsson, M. Ambrosio, L. Lastbom, V. Capra, B. Dahlen, A. 
Ryrfeldt, G.C. Folco, S.E. Dahlen, “Antagonism of thromboxane 
receptors by diclofenac and lumiracoxib,” Br J Pharmacol. 152:1185-
1195, 2007. 
[9] A. Shenker, P. Goldsmith , C. G. Unson, & A. M. Spiegel, ″The G 
protein coupled to the thromboxane A2 receptor in human platelets is a 
member of the novel Gq family. J Biol Chem 266, 9309−9313, 1991. 
[10] S. Offermanns, K. Laugwitz, K. Spicher, & G. Schultz, ″ G proteins of 
the G12 family are activated via thromboxane A2 and thrombin 
receptors in human platelets,” Proc Natl Acad Sci U S A. 91, 
504−508,1994. 
[11] DE. Mais, D. De Holl, H. Sightler, PV. Halushka, “Different 
pharmacologic activities for 13-azapinane thromboxane A2 analogs in 
platelets and blood vessels,” Eur J Pharmacol. 148(3):309–315,1988. 
[12] S.Ratti, P.Quarato, C.Casagrande, R. Fumaagalli, A. Corsini, 
“Picotamide, an antithromboxane agent, inhibits the migration and 
proliferation of arterial myocytes,” Eur J Pharmacol. 355(1):77–83, 
1998. 
[13] SM. Miggin, BT. Kinsella, “Thromboxane A (2) receptor mediated 
activation of the mitogen activated protein kinase cascades in human 
uterine smoothmuscle cells,” Biochim Biophys Acta. 1539(1–2):147–
162, 2001. 
[14]  L. Walch, V. de Montpreville, C. Brink, X. Norel, “Prostanoid EP(1)- 
and TP-receptors involved in the contraction of human pulmonary 
veins,”. Br J Pharmacol;134(8):1671–1678, 2001. 
[15] G.E. Rovati, A. Sala, V. Capra, S.E. Dahlen, G. Folco, “Dual 
COXIB/TP antagonists: a possible new twist in NSAID pharmacology 
and cardiovascular risk,” Trends Pharmacol Sci. 31:102-107, 2010. 
[16] M. Bertinaria, M.A. Shaikh, C. Buccellati, C. Cena, B. Rolando, L. 
Lazzarato, R. Fruttero, A. Gasco, M. Hoxha, V. Capra, A. Sala, G.E. 
Rovati. “Designing Multitarget Anti-inflammatory Agents: Chemical 
Modulation of the Lumiracoxib Structure toward Dual Thromboxane 
Antagonists-COX-2 Inhibitors,” ChemMedChem. 7:1647-1660, 2012. 
 
 
 
M. Hoxha was born in Vlore, Albania on 22 June 1988. She is a PhD 
Candidate at the University of Milan, Graduate School in Pharmacological 
Sciences. She is a graduate of United World College of South East Asia, 
Singapore and she received her degree in Pharmacy in 2012 from the 
University of Milan, Italy. 
She actually attends her PhD studies at the Laboratory of Molecular 
Pharmacology, Department of Pharmacological Sciences, University of Milan. 
Her interests have focus on Cardiovascular and Inflammation field in 
particular COXIBS with dual activity: TP antagonist/COXIB; study of 
thromboxane prostanoid receptor (TP) and characterization of its highly 
functional mutants with respect to homo/heterodimer formation and their 
regulation by different agonists. 
Dr. Hoxha is a member of EPSA and in 2009 she was given the Research 
Award in memory of Professor Elena Sottocornola form the University of 
Milan, Italy, whereas in 2006 she obtained the Bilingual Award from United 
World College of South East Asia, Singapore. 
World Academy of Science, Engineering and Technology
International Journal of Medical, Health, Pharmaceutical and Biomedical Engineering Vol:8 No:4, 2014 
208International Scholarly and Scientific Research & Innovation
In
te
rn
at
io
na
l S
ci
en
ce
 In
de
x 
V
ol
:8
, N
o:
4,
 2
01
4 
w
as
et
.o
rg
/P
ub
lic
at
io
n/
99
98
29
9
